Evaluation of the effect onset with Propiverine hydrochloride(BUP-4) in Female Patients diagnosed as overactive bladder.

Evaluation of the effect onset with Propiverine hydrochloride(BUP-4) in Female Patients diagnosed as overactive bladder. - Evaluation of the effect onset with Propiverine hydrochloride(BUP-4) in Female Patients diagnosed as overactive bladder.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012512

Enrollment

Registered

2015-04-01

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

Propiverine hydrochloride(BUP-4) 20mg will be orally administered once day after breakfast after observation period(2days)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Female Patients diagnosed as overactive bladder. 2) 20 years old or more patients, 3) Residual urine volume is less than 50mL

Exclusion criteria

Exclusion criteria: 1) Patients with bladder stone, urethral calculus, interstitial cystitis 2) Patients with endometriosis required for surgery and pelvic organ prolapse 3) Patients with history of treatment OAB within 2 months 4) Patients with treatment for cancer 5) Patients with lower urinary tract symptom 6) Patients with symptomatic urinary tract infection 7) Patients with polyuria (>=3000mL /day) 8) Other severe complications, such as uncontrolled diabetes mellitus, uncontrolled hypertension) 9) Patients with angle-closure glaucoma 10) Patients with severe heart dysfunction, renal dysfunction, liver dysfunction 11) Women who are capable of pregnancy, intend to get pregnant 12) Pregnant or lactating women 13) Judged ineligible based on physicians' decision

Design outcomes

Primary

Measure	Time frame
change of frequency of urination in 24 hours	—

Secondary

Measure	Time frame
change of urinary urgency in 24 hours, change of urinary incontinence in 24 hours, change of OABSS score, change of KHQ score, Residual urine volume, adverse event	—

Countries

Japan

Contacts

Public ContactSatoshi Washino

Jichi Saitama Medical Center Department of Urology

suwajiisan@jichi.ac.jp048-647-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026